Tricida Inc. logo

TCDA

NASDAQ

Tricida Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2018
$0.10-0.02 (-19.25%)
Website
News25/Ratings2

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Latest news

25 items